RxDoctor Payments Data

Evelyn Fu, MD

Retina Specialist · Puyallup, WANPI 1881868370

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (49.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Alimera Sciences, Inc. accounts for 67.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $16,592 and has fallen 99.5% since, to $91 in 2025.

$21,873in general payments, 2019–2025

Across 93 payments — averaging $235.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$15K
  • AbbVie$6K
  • Alcon$420
  • Eyepoint US, Inc.$134
  • Regeneron Healthcare Solutions, Inc.$134
  • Novartis$98
  • plus $314 from 12 others

What the payments were for

  • Consulting fees$5,25024%
  • Speaking & faculty fees$10,81649%
  • Travel & lodging$3,00914%
  • Food & beverage$2,79813%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,535,406
Medicare patients
762
Services billed
33,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SimbrinzaBrinzolamide/Brimonidine Tart38$7,681
Prednisolone Acetate144$7,179
Ketorolac Tromethamine179$6,849
Atropine Sulfate98$3,688
Ciprofloxacin Hcl100$1,367
Dorzolamide Hcl48$958
Timolol Maleate100$899
Brimonidine Tartrate54$879
Latanoprost87$490
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat15$152
ErythromycinErythromycin Base13$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$420$7,68138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few retina specialist providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other retina specialist in Puyallup

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →